SOURCE: StockCall

StockCall

June 01, 2011 09:05 ET

Analyst Research on Perrigo Co. and Auxilium Pharmaceuticals Inc. - Drug Related Products Industry Steady

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Jun 1, 2011) - www.stockcall.com/ offers investors comprehensive research on the Drug Related Products industry and has completed analytical research on Perrigo Co. (NASDAQ: PRGO) and Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). Register with us today at www.stockcall.com/ to have free access to these researches.

The drug related products industry saw strong first quarter sales as a whole. An increased consumer preference for generic drugs and changes in drug status were the primary revenue drivers. Increased research and development costs did partially offset revenues for some companies though. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Drug Related Products industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the Drug Related Products industry can have easy and free access to our analyst research and opinions on Perrigo Co. and Auxilium Pharmaceuticals Inc.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

Companies within the drug related products industry benefit from the transition of prescription drugs to the over the counter variety. This process, dubbed 'Rx-to-OTC switch', could be a substantial revenue generator in the next few years. The process is contingent upon the Food and Drug Administration approval though. A good example of this would be Perrigo Co.'s partners receiving approval earlier this year to market Allegra and Allegra D. The company believes annual sales could reach $500-$600 million. Investors looking for free research on Perrigo Co. are welcome to sign up at www.stockcall.com/PRGO01611.pdf for our new report.

There are a few factors working against the industry though. Greater competition has made research and development spending increasingly important. Auxilium Pharmaceuticals Inc., for example, saw R&D spending rise 85% in the quarter. Investors looking for complimentary research on Auxilium Pharmaceuticals Inc. are welcome to sign up at www.stockcall.com/AUXL010611.pdf for our new report.

Moving forward, the drug related products industry is in a good position at the moment. While there are a few factors that could slow growth, steady consumer demand and changing drug statuses could help many widen margins in the coming months. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information